

Patrizia Vici

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1210804/patrizia-vici-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150
papers

2,553
citations

29
h-index

40
g-index

155
ext. papers

3,036
ext. citations

5.1
avg, IF

4.46
L-index

#	Paper	IF	Citations
150	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211059873	5.4	1
149	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.. <i>Frontiers in Oncology</i> , 2021 , 11, 769280	5.3	3
148	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103176	7	6
147	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021 , 18, 2245-2250	3.7	2
146	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. <i>Cells</i> , 2021 , 10,	7.9	1
145	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 103-109	4.4	0
144	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2065-2077	8.9	6
143	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 279	12.8	12
142	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020 , 8,	5.3	16
141	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
140	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020 , 235, 7900-7910	7	11
139	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020 , 8,	5.3	4
138	Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer. <i>Clinical and Translational Medicine</i> , 2020 , 10, e199	5.7	0
137	Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 105-111	3.5	7
136	Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. <i>Medicine (United States)</i> , 2020 , 99, e21211	1.8	1
135	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020 , 15, 30-37	2.4	
134	Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors. <i>Oncology</i> , 2020 , 98, 10-15	3.6	4

133	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020 , 146, 1917-1929	7.5	3
132	Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 9-20	3.5	25
131	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial. <i>Cancers</i> , 2020 , 12,	6.6	1
130	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919853192	5.4	1
129	Fertility Preservation and Reproductive Health in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e389-e390	4.7	1
128	The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019 , 19, e501-e510	3	8
127	Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPIO study. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 990-993	3.6	2
126	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019 , 17, 99	8.5	31
125	Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. <i>Breast Journal</i> , 2019 , 25, 444-449	1.2	2
124	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1924-1934	8.9	33
123	Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	13
122	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019 , 10, 5926-5934	4.5	16
121	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019 , 10, 5903-5914	4.5	8
120	Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report. <i>Medicine (United States)</i> , 2019 , 98, e17135	1.8	1
119	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. <i>Breast</i> , 2019 , 44, 33-38	3.6	52
118	A multicenter RETrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019 , 20, 192-200	4.6	17
117	Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPIO study. <i>Future Oncology</i> , 2019 , 15, 33-44	3.6	11
116	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019 , 234, 7708-7717	7	16

115	The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. <i>OncImmunity</i> , 2018 , 7, e1457602	7.2	6
114	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018 , 19, 328-334	4.6	10
113	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1396-1401	7	9
112	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018 , 233, 2313-2323	7	17
111	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018 , 16, 129	8.5	7
110	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018 , 7, 55	6.6	6
109	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018 , 16, 22	8.5	10
108	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , 2018 , 9, 31877-31887	3.3	2
107	Dual-time ^{18}F -FDG PET/CT for the detection of liver metastases in breast cancer. <i>Nuclear Medicine Communications</i> , 2018 , 39, 1183-1189	1.6	7
106	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	38
105	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018 , 16, 247	8.5	5
104	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. <i>Breast</i> , 2017 , 32, 79-86	3.6	10
103	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017 , 140, 2587-2595	7.5	21
102	Body mass index modifies the relationship between γH2AX , a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017 , 17, 101	4.8	11
101	The clinical implementation of primary HPV screening. <i>International Journal of Gynecology and Obstetrics</i> , 2017 , 136, 266-271	4	2
100	ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. <i>Future Oncology</i> , 2017 , 13, 1517-1525	3.6	3
99	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , 2017 , 22, 648-654	5.7	8
98	Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?. <i>Breast</i> , 2017 , 35, 218-219 ³⁶		

97	Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer. <i>Head and Neck</i> , 2017 , 39, 1761-1769	4.2	17
96	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017 , 18, 339-346	4.6	13
95	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017 , 232, 2246-2252	7	9
94	Niraparib in ovarian cancer: results to date and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 579-588	5.4	20
93	1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer. <i>Tumori</i> , 2017 , 103, 525-536	1.7	8
92	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 143	12.8	1
91	Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 191	12.8	3
90	Bevacizumab in ovarian cancer: A critical review of phase III studies. <i>Oncotarget</i> , 2017 , 8, 12389-12405	3.3	77
89	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. <i>Oncotarget</i> , 2017 , 8, 54528-54536	3.3	10
88	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017 , 7, 10597	4.9	11
87	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017 , 7, 8078	4.9	13
86	A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017 , 232, 1571-1578	7.1578	12
85	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017 , 8, 56921-56931	3.3	41
84	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017 , 8, 99336-99346	3.9	55
83	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 106, 132-42	7	7
82	Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons. <i>Tumori</i> , 2016 , 102, 472-480	1.7	8
81	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. <i>Scientific Reports</i> , 2016 , 6, 35121	4.9	5
80	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016 , 231, 986-91	7	11

79	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 62	12.8	19
78	Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 years or younger: Evidence from a historic cohort. <i>Cancer Biology and Therapy</i> , 2016 , 17, 470-6	4.6	5
77	Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions. <i>European Journal of Cancer</i> , 2016 , 58, 52-61	7.5	7
76	Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 31-49	5.9	23
75	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016 , 11, e0149872	3.7	8
74	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016 , 7, 17932-44	3.3	26
73	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. <i>Oncotarget</i> , 2016 , 7, 43188-43198	3.5	26
72	Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. <i>International Journal of Endocrinology</i> , 2016 , 2016, 8671762	2.7	18
71	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016 , 7, 516-22	4.5	4
70	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016 , 11, e0156221	3.7	2
69	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016 , 5, e1160187	7.2	24
68	Surgical and Oncological Outcome of Robotic Surgery Compared With Laparoscopic and Abdominal Surgery in the Management of Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 539-46	3.5	20
67	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016 , 231, 2541-7	7	10
66	Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. <i>Clinical Breast Cancer</i> , 2015 , 15, e131-7	3	21
65	Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. <i>Journal of Cellular Physiology</i> , 2015 , 230, 1708-12	7	5
64	Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. <i>Advances in Therapy</i> , 2015 , 32, 10-30	4.1	47
63	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 26	12.8	13
62	Metformin and breast cancer: basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015 , 41, 441-7	14.4	11

61	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015 , 368, 20-25	9.9	15
60	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. <i>Expert Reviews in Molecular Medicine</i> , 2015 , 17, e14	6.7	55
59	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0136731	3.7	7
58	Triple-negative breast cancer: new perspectives for targeted therapies. <i>OncoTargets and Therapy</i> , 2015 , 8, 177-93	4.4	94
57	Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1704-9	4.6	5
56	Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 1253-7	3.5	34
55	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 53	22.4	30
54	Triple positive breast cancer: a distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015 , 41, 69-76	14.4	56
53	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015 , 6, 42773-80	2.3	13
52	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014 , 17, 718-24	7.6	18
51	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 73-80	4.4	22
50	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 227-35	4.4	16
49	Fertility drugs, reproductive strategies and ovarian cancer risk. <i>Journal of Ovarian Research</i> , 2014 , 7, 51	5.5	18
48	Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. <i>Journal of Cancer</i> , 2014 , 5, 320-7	4.5	47
47	Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients. <i>Journal of Cancer</i> , 2014 , 5, 398-405	4.5	7
46	Emerging biological treatments for uterine cervical carcinoma. <i>Journal of Cancer</i> , 2014 , 5, 86-97	4.5	45
45	Cancer stem cells: are they responsible for treatment failure?. <i>Future Oncology</i> , 2014 , 10, 2033-44	3.6	12
44	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 599-607	4.4	32

43	Hot flushes in women with breast cancer: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 185-98	3.5	4
42	Immunologic treatments for precancerous lesions and uterine cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 29	12.8	32
41	Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. <i>PLoS ONE</i> , 2014 , 9, e94063	3.7	6
40	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014 , 5, 10382-92	3.3	10
39	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014 , 5, 9619-23	3.3	30
38	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 1229-40	4.9	6
37	Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 48	12.8	62
36	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 67	12.8	16
35	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 49	12.8	13
34	Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 89	12.8	8
33	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 699-706	4	15
32	Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy. <i>Gynecological Endocrinology</i> , 2013 , 29, 25-9	2.4	14
31	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 119-23	4.4	28
30	Breast cancer risk after exposure to fertility drugs. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 149-57	3.5	8
29	Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials. <i>PLoS ONE</i> , 2013 , 8, e69269	3.7	37
28	Docetaxel, oxaliplatin, and capecitabine (DOX) combination chemotherapy for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15065-e15065	2.2	1
27	Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient. <i>Tumori</i> , 2013 , 99, e127-30	1.7	2
26	Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 687-93	3.5	8

25	A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 39	12.8	20
24	Current role and safety profile of aromatase inhibitors in early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1253-63	3.5	23
23	Making the right choice in the adjuvant chemotherapy of primary breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 10-12	1.6	1
22	A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. <i>Oncology</i> , 2008 , 75, 175-81	3.6	11
21	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. <i>PLoS ONE</i> , 2008 , 3, e1592	3.7	45
20	Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. <i>Anticancer Research</i> , 2008 , 28, 1245-58	2.3	8
19	Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3048-55	2.2	33
18	Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6908-18	2.2	79
17	Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer. <i>Anticancer Research</i> , 2005 , 25, 1309-14	2.3	1
16	Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. <i>Clinical Cancer Research</i> , 2004 , 10, 1360-5	12.9	37
15	Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients. <i>Cancer Investigation</i> , 2004 , 22, 650-3	2.1	4
14	Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. <i>Seminars in Oncology</i> , 2004 , 31, 13-9	5.5	21
13	Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3462-8	2.2	61
12	First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2689-94	2.2	29
11	Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2001 , 68, 9-19	4.4	30
10	Docetaxel in patients with anthracycline-resistant advanced breast cancer. <i>Oncology</i> , 2001 , 60, 60-5	3.6	17
9	Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2000 , 126, 722-9	4.9	18
8	First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. <i>Oncology</i> , 2000 , 58, 3-7	3.6	14

7	Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity. <i>Journal of Nuclear Cardiology</i> , 1997 , 4, 502-8	2.1	18
6	Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer. <i>Oncology</i> , 1996 , 53, 16-8	3.6	16
5	Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. <i>Cancer</i> , 1993 , 72, 502-5	6.4	34
4	Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991 , 117, 61-4	4.9	11
3	5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1990 , 13, 204-7	2.7	8
2	A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. <i>Cancer</i> , 1989 , 64, 2431-6	6.4	43
1	5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. <i>Oncology</i> , 1989 , 46, 1-5	3.6	34